Ironwood Pharmaceuticals (NASDAQ:IRWD) Raised to "Strong-Buy" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Ironwood Pharmaceuticals from “buy” to “strong-buy.” Across analysts, the stock has a “Moderate Buy” consensus rating and an average price target of $6.23.
• Ironwood reported quarterly earnings of $0.36 per share, above the $0.32 estimate, and revenue of $133.04 million, exceeding the $119.99 million estimate cited in the report.
• The company raised its 2026 revenue guidance to $485 million–$510 million and increased its EBITDA outlook, citing stronger expected Linzess sales and profitability.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Saturday, Wall Street Zen reports.

Other equities research analysts also recently issued research reports about the stock. Jefferies Financial Group upgraded shares of Ironwood Pharmaceuticals to a "hold" rating in a research note on Friday, September 25th. Zacks Research lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 30th. Finally, Weiss Ratings raised shares of Ironwood Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $6.23.

Ironwood Pharmaceuticals Stock Performance

NASDAQ:IRWD opened at $4.39 on Friday. The firm's 50-day simple moving average is $3.91 and its 200 day simple moving average is $3.97. The firm has a market cap of $725.40 million, a price-to-earnings ratio of 4.44 and a beta of 0.25. Ironwood Pharmaceuticals has a 52 week low of $1.88 and a 52 week high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.04. Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%. The company had revenue of $133.04 million during the quarter, compared to analyst estimates of $119.99 million. Sell-side analysts anticipate that Ironwood Pharmaceuticals will post 1.10 EPS for the current year.

Institutional Trading of Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of IRWD. Dimensional Fund Advisors LP grew its position in Ironwood Pharmaceuticals by 529.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,082,055 shares of the biotechnology company's stock valued at $7,307,000 after purchasing an additional 1,751,219 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter valued at about $2,142,000. Pacer Advisors Inc. purchased a new position in shares of Ironwood Pharmaceuticals during the 1st quarter valued at approximately $3,982,000. CWA Asset Management Group LLC raised its position in Ironwood Pharmaceuticals by 71.7% in the third quarter. CWA Asset Management Group LLC now owns 498,643 shares of the biotechnology company's stock valued at $1,980,000 after purchasing an additional 208,277 shares during the period. Finally, Globeflex Capital L P acquired a new position in shares of Ironwood Pharmaceuticals during the 2nd quarter worth about $1,094,000.

Key Headlines Impacting Ironwood Pharmaceuticals

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Ironwood reported Q3 adjusted earnings of $0.36 per share, above analyst expectations, while net income rose 49% year over year. It raised 2026 revenue guidance to $485 million–$510 million, above the roughly $470.5 million consensus, and increased its EBITDA outlook. Management also cited stronger Linzess sales expectations and profitability. Ironwood Q3 net income rises and outlook increases
• Neutral Sentiment: Revenue commentary was inconsistent: one Zacks headline described revenue as missing expectations, while reported figures of $133.04 million exceeded the estimate of $119.99 million cited elsewhere. Zacks Q3 earnings and outlook coverage

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a gastrointestinal-focused biopharmaceutical company headquartered in Boston, Massachusetts. The company discovers, develops, and commercializes medicines intended to treat disorders affecting the gastrointestinal tract, with an emphasis on conditions involving gut motility and visceral sensitivity.

Ironwood's principal commercial product is Linzess (linaclotide), marketed in the United States in collaboration with AbbVie. Linzess is approved for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.